Information Provided By:
Fly News Breaks for September 13, 2017
Sep 13, 2017 | 07:28 EDT
Deutsche Bank analyst Esther Rajavelu recently met with two compounding pharmacists to assess their ability and motivation to switch patients to TX-001, TherapeuticsMD's single pill combination for vasomotor symptoms in menopausal women. The analyst remains optimistic over "strong uptake in this patient segment." The company's opportunity from compounded hormone therapies to TX-001 remains underappreciated, Rajavelu tells investors in a research note. The analyst models launch in late 2018 with revenue reaching $1B in five years. Rajavelu reiterates a Buy rating on the shares with a $10 price target.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.